Q32 Bio (QTTB) Competitors $1.91 +0.04 (+1.87%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.89 -0.02 (-1.05%) As of 08/22/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QTTB vs. PMVP, CELU, IGMS, JMAC, MGX, ASRT, CABA, INMB, STRO, and GNTAShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include PMV Pharmaceuticals (PMVP), Celularity (CELU), IGM Biosciences (IGMS), Maxpro Capital Acquisition (JMAC), Metagenomi (MGX), Assertio (ASRT), Cabaletta Bio (CABA), INmune Bio (INMB), Sutro Biopharma (STRO), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. Its Competitors PMV Pharmaceuticals Celularity IGM Biosciences Maxpro Capital Acquisition Metagenomi Assertio Cabaletta Bio INmune Bio Sutro Biopharma Genenta Science PMV Pharmaceuticals (NASDAQ:PMVP) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Does the media refer more to PMVP or QTTB? In the previous week, Q32 Bio had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 1 mentions for Q32 Bio and 0 mentions for PMV Pharmaceuticals. Q32 Bio's average media sentiment score of 0.25 beat PMV Pharmaceuticals' score of 0.00 indicating that Q32 Bio is being referred to more favorably in the news media. Company Overall Sentiment PMV Pharmaceuticals Neutral Q32 Bio Neutral Do insiders & institutionals have more ownership in PMVP or QTTB? 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is PMVP or QTTB more profitable? PMV Pharmaceuticals' return on equity of -47.94% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets PMV PharmaceuticalsN/A -47.94% -43.82% Q32 Bio N/A -2,709.70%-61.16% Do analysts prefer PMVP or QTTB? PMV Pharmaceuticals currently has a consensus price target of $5.50, indicating a potential upside of 271.62%. Q32 Bio has a consensus price target of $12.17, indicating a potential upside of 537.00%. Given Q32 Bio's higher possible upside, analysts clearly believe Q32 Bio is more favorable than PMV Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has better earnings & valuation, PMVP or QTTB? Q32 Bio has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPMV PharmaceuticalsN/AN/A-$58.71M-$1.57-0.94Q32 Bio$1.16M20.09-$47.73M-$4.30-0.44 SummaryQ32 Bio beats PMV Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.30M$3.12B$5.82B$9.78BDividend YieldN/A2.23%4.40%4.06%P/E Ratio-0.4421.0031.3026.05Price / Sales20.09356.92455.29117.98Price / CashN/A44.5038.0259.36Price / Book-1.918.129.536.60Net Income-$47.73M-$54.72M$3.26B$265.65M7 Day Performance-3.05%2.62%2.13%1.99%1 Month Performance-17.32%3.25%3.21%0.45%1 Year Performance-95.16%10.82%30.18%18.87% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.5583 of 5 stars$1.91+1.9%$12.17+537.0%-95.2%$23.30M$1.16M-0.4439News CoverageShort Interest ↓PMVPPMV Pharmaceuticals2.2912 of 5 stars$1.40-5.4%$5.50+292.9%-4.5%$78.43MN/A-0.8950CELUCelularity0.6958 of 5 stars$3.23-0.3%N/A+19.9%$77.60M$54.22M-1.22220News CoverageAnalyst UpgradeIGMSIGM Biosciences4.288 of 5 stars$1.29+1.6%$5.50+326.4%N/A$76.57M$2.68M-1.43190JMACMaxpro Capital AcquisitionN/A$5.68+1.7%N/A+4,514.2%$76.20MN/A0.002,021MGXMetagenomi2.4981 of 5 stars$1.83-4.7%$13.00+610.4%-40.1%$71.77M$52.29M-0.87236Trending NewsAnalyst ForecastAnalyst RevisionASRTAssertio2.0211 of 5 stars$0.73-0.5%$2.63+262.1%-38.6%$69.82M$124.96M-2.2720CABACabaletta Bio2.0911 of 5 stars$1.33-2.2%$14.43+984.9%-73.3%$69.01MN/A-0.4950INMBINmune Bio1.9584 of 5 stars$2.40-6.3%$18.40+666.7%-65.3%$68.06M$10K-0.9710STROSutro Biopharma4.2105 of 5 stars$0.77-3.7%$6.11+691.4%-82.9%$68.02M$62.04M-0.31240Analyst DowngradeGNTAGenenta Science1.8412 of 5 stars$3.54-4.7%$25.00+607.2%-14.0%$67.87MN/A0.007Gap UpHigh Trading Volume Related Companies and Tools Related Companies PMV Pharmaceuticals Competitors Celularity Competitors IGM Biosciences Competitors Maxpro Capital Acquisition Competitors Metagenomi Competitors Assertio Competitors Cabaletta Bio Competitors INmune Bio Competitors Sutro Biopharma Competitors Genenta Science Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QTTB) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access